
    
      To give a chance of continuous use of 0.1% FK506 ophthalmic suspension to patients with
      vernal keratoconjunctivitis who were enrolled in the FJ-506D-AC09 study, long-term safety and
      efficacy were evaluated. Primary efficacy endpoint was the mean change from the baseline
      (before the treatment) in total score for objective clinical signs.
    
  